Agenus stock analysis
Agenus (AGEN) Stock Price & Analysis
AGEN Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 239.28M
- Enterprise Value
- CHF 1.01B
- Total Cash (Recent Filing)
- CHF 66.94M
- Total Debt (Recent Filing)
- CHF 39.46M
- Price to Earnings (P/E)
- 8.6
- Beta
- N/A
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- -0.14
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Revenue And Margins
The latest results show substantial improvement in revenue and reported profitability, indicating stronger contribution from collaborations, licensing, or services. If Agenus can sustain this performance, higher margins could support reinvestment in its pipeline and reduce dependence on external financing over the next several quarters.
Clinical Durability Signal
Durable responses in heavily pretreated metastatic colorectal cancer provide meaningful clinical validation for Agenus’s immuno-oncology approach. Although the evidence remains from an early-stage study, persistence of benefit could strengthen partnering prospects and support future development of the BOT+BAL franchise.
Lower Absolute Debt
The sharp reduction in reported debt improves the company’s absolute debt burden compared with the prior year and may reduce near-term repayment pressure. This gives management more flexibility to allocate resources toward clinical development, although the benefit is tempered by thin equity and continuing cash consumption.
Bears Say
Persistent Cash Burn
Agenus remains far from self-funding, with operating and free cash flow materially negative after a multi-year pattern of burn. Continued development spending without sustained product revenue or substantial partnership economics increases reliance on financing and could constrain the pace of pipeline investment.
Fragile Balance Sheet
Very thin equity leaves Agenus with limited financial cushion if operating results weaken, while the elevated debt-to-equity ratio magnifies balance-sheet sensitivity. This combination can restrict strategic flexibility and make future capital needs more consequential for shareholders and creditors.
Financing And Dilution Pressure
The amended loan preserves access to financing but carries a high interest rate and uses equity for part of the extension fee. That structure raises ongoing funding costs and creates potential dilution, reinforcing the challenge of financing operations while cash generation remains negative.
Agenus News
AGEN FAQ
What is Agenus’s market cap?
When is Agenus’s upcoming earnings report date?
How were Agenus’s earnings last quarter?
Is Agenus overvalued?
Does Agenus pay dividends?
What is Agenus’s EPS estimate?
What happened to Agenus’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Agenus?
What is the TipRanks Smart Score and how is it calculated?
Agenus Stock Smart Score
Company Description
Agenus
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Garo H. Armen
- Employees
- 81
- Website
- www.agenusbio.com
- Address
- 3 Forbes Road, Lexington, MA, 02421-7305, US
Agenus (AGEN) Earnings & Revenues
AGEN Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted several positive developments, including strategic hires, promising BOT/BAL data, and multiple capital proposals which could strengthen the company's financial position. However, financial metrics such as a decreased cash balance and lower revenue compared to the previous year, alongside ongoing regulatory challenges, present notable challenges. The overall sentiment is cautiously optimistic as the highlights and lowlights are balanced.
View all CH:AGEN earnings summaries











